Workflow
NAS
icon
Search documents
X @Investopedia
Investopedia· 2025-06-26 11:00
The Invesco QQQ Trust, which tracks the Nasdaq 100, closed at a record high for the second straight day on Wednesday. Monitor these crucial chart levels. https://t.co/a8X0m7YtLD ...
Dal buio alla luce: quando la vita chiede di rinascere | Sara Ercolino | TEDxHensemberger Youth
TEDx Talks· 2025-06-25 15:52
[Musica] Nascere è un atto involontario. Nessuno sceglie di venire al mondo. Nessuno decide il momento, il luogo, la famiglia, le circostanze.Ci troviamo gettati in un'esistenza che non abbiamo chiesto, con un nome che non abbiamo scelto, in un corpo che impariamo a conoscere solo col tempo. Nascere all'inizio, sì, ma non è ancora vita. È un dono e allo stesso tempo un destino, perché ciò che ci rende davvero vivi non è nascere, ma rinascere.Rinascere non è un privilegio riservato a pochi, è una necessità u ...
La nascita è solo l'inizio | Edoardo Guarnaccia | TEDxHensemberger Youth
TEDx Talks· 2025-06-25 15:43
[Musica] Se aveste la possibilità di provare oggi le sensazioni fisiche ed emotive di quando siete venuti al mondo, accettereste di farlo. Tutti noi nasciamo all'interno di una sala parto, già piangendo con un riflettore che ci punta contro. Tutto di un tratto siamo.Fino a pochi istanti prima non eravamo e ora siamo immersi in un posto sconosciuto, più freddo e diverso. Eppure in quella meraviglia non siamo soli. C'è qualcuno che ci accoglie e fa sentire parte di qualcosa.La vita ha inizio e siamo già in re ...
Looking back DeepSeek wasn't all that meaningful for tech stocks, says Jim Cramer
CNBC Television· 2025-06-24 23:39
'Mad Money' host Jim Cramer talks tech's big comeback as NASDAQ-100 hits record highs. ...
Nuvalent (NUVL) Earnings Call Presentation
2025-06-24 13:53
Pipeline Programs and Milestones - Nuvalent is advancing parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development, with potential for first FDA approval in 2026[4] - The company plans to report pivotal data for TKI pre-treated ROS1+ NSCLC from the ARROS-1 trial in 1H 2025 and complete rolling NDA submission in Q3 2025[14] - Topline pivotal data for TKI pre-treated ALK+ NSCLC from the ALKOVE-1 trial is anticipated by year-end 2025, with ALKAZAR Phase 3 trial for TKI-naïve ALK+ NSCLC planned to initiate in early 2H 2025[14, 205] - NVL-330 for HER2-altered NSCLC is in Phase 1a/1b investigation, with additional discovery research programs ongoing[12, 205] Zidesamtinib (NVL-520) for ROS1+ NSCLC - In TKI pre-treated ROS1+ NSCLC patients, the ORR was 44% (51/117), with 78% (95% CI: 62, 88) DOR ≥ 12 months and 62% (95% CI: 28, 84) DOR ≥ 18 months[73] - In patients with prior crizotinib or entrectinib only ± chemotherapy, the ORR was 51% (28/55), with 93% (95% CI: 74, 98) DOR ≥ 12 months and 93% (95% CI: 74, 98) DOR ≥ 18 months[80] - Zidesamtinib demonstrated CNS activity, with an IC-ORR of 48% (27/56) in any prior ROS1 TKI ± chemotherapy and 85% (11/13) in prior crizotinib only ± chemotherapy[90] - The safety profile of zidesamtinib was generally well-tolerated, with peripheral edema reported in 36% of patients, constipation in 17%, blood CPK increased in 16%, fatigue in 16%, and dyspnea in 15%[96] - In TKI-naïve patients with ROS1+ NSCLC, the ORR was 89% (31/35), with 96% (95% CI: 76, 99) DOR ≥ 6 months and 96% (95% CI: 76, 99) DOR ≥ 12 months[103] Neladalkib (NVL-655) for ALK+ NSCLC - In a heavily pre-treated ALK+ solid tumor population, 51% had any secondary ALK mutation, 26% had a compound ALK mutation, and 56% had a history of CNS metastasis[140, 141] - In all NSCLC response evaluable patients, across all doses, the ORR was 38% (39/103), with a mDOR of 144 months and 78% DOR > 6 months[149] - In patients with any ALK resistance mutation at RP2D, the ORR was 55% (12/22), with a mDOR not reached and 100% DOR > 6 months[158] - The preliminary safety profile of neladalkib was consistent with its ALK-selective design, with ALT increased in 34% of patients, AST increased in 30%, constipation in 16%, dysgeusia in 13%, and nausea in 12%[166] Market Overview - The combined worldwide sales for ALK and ROS1 TKIs in 2024 were approximately $31 billion[27]
Nuvalent (NUVL) Update / Briefing Transcript
2025-06-24 13:00
Summary of Nuvalent Conference Call Company Overview - **Company**: Nuvalent - **Focus**: Development of targeted therapies for cancer, specifically for ROS1 positive non-small cell lung cancer (NSCLC) with their product candidate, Zydastantinib [2][5][6] Industry Context - **Industry**: Oncology, specifically targeting ROS1 positive non-small cell lung cancer - **Current Landscape**: Four FDA approved therapies exist for ROS1 positive NSCLC, each with limitations such as inadequate CNS penetrance and resistance mutations [10][11] Key Points and Arguments Product Development and Clinical Trials - **Zydastantinib**: First and only ROS1 selective compound designed to address key medical needs, including CNS penetrance and resistance mutations [12][8] - **ARRIS-one Trial**: Ongoing clinical trial evaluating Zydastantinib, with a focus on heavily pretreated patients [12][13] - **Enrollment**: As of September 2023, enrollment in the Phase II portion began, targeting both TKI pretreated and naive patients [13][14] Clinical Data Highlights - **Efficacy**: - Overall response rate (ORR) in TKI pretreated patients was 44%, with a duration of response (DOR) rate of 62% at 18 months [17][18] - In patients who received prior crizotinib only, ORR was 68% with no progression events among responders [21][43] - In TKI naive patients, ORR was 89% with a DOR rate of 96% at 12 months [27][28] - **CNS Activity**: - Intracranial ORR was 48% in patients with measurable CNS lesions, with a complete response (CR) rate of 20% [23][24] - In patients who received crizotinib only, intracranial ORR was 85% [24][49] Safety Profile - **Adverse Events**: Zydastantinib was generally well tolerated, with low rates of dose modifications (10%) and discontinuations (2%) due to adverse events [25][26] - **Common Adverse Events**: Peripheral edema (36%), constipation (17%), and fatigue (16%) were the most frequently reported [25] Regulatory and Commercial Strategy - **NDA Submission**: Planned rolling submission for Zydastantinib in July 2025, targeting TKI pretreated patients [29] - **FDA Engagement**: Participation in the Real Time Oncology Review (RTOR) pilot program to expedite the review process [29] - **Commercial Readiness**: Preparations for a potential launch in 2026, including building commercial teams and identifying key prescribers [30] Future Directions - **Broader Portfolio**: Nuvalent is advancing additional programs for ALK positive NSCLC and HER2 altered NSCLC, with pivotal data expected later in 2025 [31][32][33] - **Clinical Development Speed**: Rapid enrollment and execution of the ARRIS-one study, reflecting strong interest and support from the medical community [78] Additional Important Insights - **Market Opportunity**: The unique design of Zydastantinib aims to address unmet needs in the ROS1 NSCLC space, potentially leading to a compelling commercial opportunity [30][31] - **Comparative Advantage**: Zydastantinib's selective design aims to minimize off-target effects and improve patient tolerability compared to existing therapies [60][61] This summary encapsulates the critical aspects of Nuvalent's conference call, highlighting the company's innovative approach to treating ROS1 positive NSCLC and the promising data emerging from their clinical trials.
O futuro amazônico só existirá no encontro entre saberes | Maria Barcellos | TEDxAmazônia
TEDx Talks· 2025-06-23 16:01
[Música] Boa tarde a todos. É um prazer estar aqui. E o que eu quero conversar com vocês, eu quero contar uma história.Dizem que eh as pessoas quando vão envelhecendo, elas gostam de contar histórias, elas vivem do passado. Não é bem assim, mas eu gosto de contar histórias e é isso que eu vim fazer aqui. É, a história que eu vou contar, ela começa na primeira metade da década de 50, de 1950, tá certo.Estamos em 2000, 1950. Eu criança, eh, caminhando em direção ao mercado em Campo Grande, no Mato Grosso do S ...
S&P500 and Nasdaq 100: Futures Set for Volatile Open After U.S. Strikes Iran
FX Empire· 2025-06-22 07:44
Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to consider their financial situation and needs before relying on the information provided [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to perform their own research and understand the risks involved before making investment decisions [1].
ICML 2025 Oral | NAS老树开新花,NUS提出智能体超网,成本狂降55%
机器之心· 2025-06-21 04:36
本文第一作者为张桂彬,新加坡国立大学25Fall计算机科学博士生;本文在南洋理工大学的王琨博士、上海人工智能实验室的白磊老师、和中国科学技术大学的王 翔教授指导下完成。 LLM 智能体的时代,单个 Agent 的能力已到瓶颈,组建像 "智能体天团" 一样的多智能体系统已经见证了广泛的成功。但 "天团" 不是人越多越好,手动设计既费 力又不讨好,现有的智能体自动化方法又只会 "一招鲜",拿一套复杂阵容应对所有问题,导致 "杀鸡用牛刀",成本高昂。 现在,一篇来自新加坡国立大学、上海 AI Lab、同济大学等机构并被 ICML 2025 接收为 Oral Presentation 的论文,为我们带来了全新的解题思路。 他们将神经网络架构搜索(NAS)的超网络(Supernet)思想引入 Agent 领域,首创了一个名为 "智能体超网"(Agentic Supernet)的概念。它不再寻找一个固定的 最佳 "阵容",而是根据任务难度,动态 "剪" 出一个量身定制的智能体团队。结果有多惊艳?性能超越现有方法最高 11.82%,推理成本却只有它们的 45%! Agentic Supernet: 论文地址:https:/ ...
X @Investopedia
Investopedia· 2025-06-20 01:00
Nash equilibrium is a game theory concept where optimal outcome is when there is no incentive for players to deviate from their initial strategy. https://t.co/ytQXzBcSrI ...